Agomab Reports Positive Phase 2a Results for Ontunisertib in Fibrostenosing Crohn’s Disease

FDA Expands RINVOQ® Indication for Inflammatory Bowel Disease

AstraZeneca Partners with Immunai in $85M AI-Driven IBD Deal

Phase 4 Study: Vedolizumab More Effective in Early Crohn’s Disease

CU Anschutz Study Links MAIT Cells to Gut Inflammation

SMC Approves TREMFYA® for Crohn’s Disease and Ulcerative Colitis

MRC Researchers Uncover Cell Mechanism Behind Crohn’s Fistulas

Numab and Kaken Partner on First-in-Class Multispecific Antibody for IBD

Translating Biomarkers into Clinical Strategy: Lessons from Other Immunological Diseases for IBD

By | 4 November 2025

Discuss Precision Medicine opportunities for in IBD using predictive and prognostic biomarkers, drawing parallels with immunology and Oncology programs advancing into later trials
Unpack the gap between translational biomarker insights and real-world diagnostics, including regulatory, commercial, and scalability hurdlesDiscuss challenges in moving from translation level biomarker insights to clinically validated tools